Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Oncolys Keeps 2024 Target for Japan Telomelysin Filing; Partner Talks Ongoing
Tokyo-based biotech Oncolys BioPharma gave a business update on its investigational oncolytic virus telomelysin on December 19, maintaining its plan to file the product for Japanese approval in 2024. In the update, the company said that it is slated to…
To read the full story
Related Article
- Oncolys Aims for First-Line Use of Telomelysin in Esophageal Cancer
January 19, 2026
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Oncolys Seeks Marketing License for Regenerative Medicine in Japan
November 27, 2024
- Oncolys Forms Oncolytic Virus Sales Collab with Fujifilm in Japan
February 8, 2024
- Telomelysin-Radiation Combo Hits Mark in PII Esophageal Cancer Study: Oncolys
October 17, 2023
- 2024 Japan Filing Plan for Oncolytic Virus Unchanged: Oncolys President
August 8, 2022
- PI Telomelysin Trial for Esophageal Cancer Begins in US: Oncolys
December 8, 2021
- Chugai, Oncolys to Call Off License Deal for Telomelysin
October 20, 2021
- Telomelysin Submission Likely Delayed into 2024 or Later: Oncolys/Chugai
April 15, 2021
- Telomelysin-Keytruda Combo Trial to Begin in US for Head and Neck Cancer: Oncolys
August 11, 2020
- Investigator-Initiated Study to Be Launched for Telomelysin/Radiotherapy in US: Oncolys
June 11, 2020
- 1st Patient Dosed Telomelysin Together with Radiotherapy in Japan PII Study for Esophageal Cancer: Chugai
March 5, 2020
- Oncolys Chief Wants Chugai Deal to Accelerate Telomelysin Development in Japan
May 21, 2019
- US PII Study for Telomelysin-Keytruda Combo Begins for Esophageal Cancer
May 14, 2019
- Oncolys, Chugai Ink 50 Billion Yen Licensing Pact for Telomelysin
April 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
BUSINESS
- Genmab Targets 2027 US Debut for 2 Cancer Drugs, CEO Eyes Blockbuster Potential
April 23, 2026
- Bayer Eyes 2026 Launch for Sevabertinib under “3-Plus-3” Strategy in Japan
April 23, 2026
- Lenvima-Keytruda Triplets Fail in First-Line RCC Trial
April 22, 2026
- Another Global PIII Shuttered for Arcus-Partnered TIGIT Combo: Taiho
April 22, 2026
- Imdelltra Likely to Gain Ground in 2nd-Line SCLC after Label Update: Oncologist
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…